an anti-allergic drug targeting pi3k delta
Transcription
an anti-allergic drug targeting pi3k delta
Biology / Licensing HEALTH AN ANTI-ALLERGIC DRUG TARGETING PI3K DELTA Allergy is a growing health problem which concerns millions of persons. Allergic asthma is a common disease, ranging from benign to fatal disease. Some patients are afflicted with steroid-dependent disease or treatmentrefractory disease. Novel agents are needed both for the treatment of acute asthma and for regular therapy. While novel agents are currently undergoing clinical trials there still remains a significant unmet medical need in this situation. DESCRIPTION PI3Kinase delta is an enzyme expressed by few cell types including human basophils, a type of white blood cell involved in allergy. We have developed an inhibitor of PI3Kinase delta which potently inhibits degranulation of stimulated normal human basophils and protects mice developing albumininduced allergic asthma. This treatment was well tolerated when administred over a period of several weeks and was associated with a significant reduction in the pulmonary cellular inflammatory infiltrate. ADVANTAGES / NOVELTY STAGE OF DEVELOPMENT • The PI3Kinase inhibitor which we have developed has shown significant preclinical activity with normal human stimulated basophils and in a preclinical mouse models of allergic asthma. Non regulatory chronic exposure for periods up to 4 weeks showed no sign of toxicity. Future development will include regulatory preclinical toxicity before proceeding to a first in man study in patients with severe asthma. • • • • Targeted therapy Excellent tolerance Bioavailable by oral or intravenous route Simple and low-cost synthesis APPLICATIONS • Our primary indication is severe asthma, in particular in patients relying on large daily doses of steroids and/or refractory to therapy. Efficacy will be measured by spirometric examinations. Secondary indications include other manifestation of allergy, including cutaneous and mucosal manifestations. INTELLECTUAL PROPERTY Patent pending in PCT Priority date: April 5th, 2013 (FR1353091) COLLABORATION TYPE PULSALYS looks for industrial partners and offers to grant patent license. RESEARCH TEAM Pr Charles DUMONTET Centre de Recherche en Cancérologie de Lyon UMR INSERM 1052, CNRS 5286 INSERM, CNRS, UCBL, Centre Léon Bérard PULSALYS 47, bd du 11 novembre 1918 69625 Villeurbanne Cedex www.pulsalys.fr Daphné THOMAS Tel. +33 (0)4 26 23 56 78 [email protected]